Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2004

View Archived Issues

Glufast launched in Japan

Prostaglandins suggested as a potential target in ulcerative colitis

Alvimopan improves gastrointestinal transit in POI and chronic constipation

Immunological changes induced by glatiramer acetate in an experimental colitis model

FK-778 results presented at American transplantation congress

Levetiracetam: advantageous treatment for seizures after liver transplantation

ISA-247 more potent than ciclosporin in renal transplant recipients

Valganciclovir simple, effective as CMV prophylaxis in renal transplantation

Alemtuzumab use may reduce tacrolimus toxicity in liver transplantation

Enrollment completed in phase III trial of enoximone

ProMetic achieves second milestone in AM-Pharma agreement

Biomira and Inno-centre Alberta to create spin-off company to develop L-IL-2 technology

Favrille receives SPA from FDA for FavID

FDA approves Taxotere for treatment of prostate cancer

MorphoSys and Novartis to discover and develop antibody-based therapeutic agents

Avelox approved for treatment of CAP caused by multidrug resistant S. pneumoniae

Zimycan receives approval in Belgium for treatment of diaper dermatitis

Phase 2 Discovery receives positive results from phase II trial with PD-6735

Enzo Biochem to begin phase I trial of EGS-21

Positive data reported from phase IIIb Xyrem study

Duloxetine may be safe and effective for diabetic neuropathic pain

Ziconotide could be safe and effective in malignant and nonmalignant pain

Enrollment commences in phase III Altropane trial

CRADA to develop stem cell technology for cardiovascular disease treatment

Onco TCS NDA accepted for review

inGenium aids Peregrine's development of monoclonal antibody for lymphoma

Yamanouchi presents activators of PGC-1 and mtTFA genes and their therapeutic use

New antidepressant agents with 5-HT reuptake, H1 and 5-HT2 blocking activity

Novel PDE4 inhibitors and their use covered by Takeda patent

Gruenenthal scientists design novel NOS inhibitors

New interferon inducers for topical application designed at Sumitomo

New stilbene-based immunomodulators prepared and tested at Welichem

New neurotrophic agents and their use in Parkinson's disease, ALS, stroke, etc.

Activity of LBM-415 extensively investigated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...